FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)															
Name and Address of Reporting Person* Radoff Bradley Louis					2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]						_X_ Direct	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director					
(Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE				т .	3. Date of Earliest Transaction (Month/Day/Year) 04/14/2022					Office	r (give title belo	w)	Other (specify belo	w)		
(Street) NEW YORK, NY 10022				4. If	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Form fil	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui					quired, Dispo	nired, Disposed of, or Beneficially Owned							
(Instr. 3) Da		Date	2. Transaction Date (Month/Day/Year)		Deemed ution Date, if	3. Transac Code (Instr. 8)	tion	(A) or Disposed of (D (Instr. 3, 4 and 5)		of (D)	Beneficially Owned Following Reported Transaction(s)		lowing	Form:	hip Indir Bene	7. Nature of Indirect Beneficial Ownership	
					(Monu	n/Day/Year)	Code	V	Amount	(A) or (D)	Price	(Instr. 3 and 4) Direct or India (I) (Instr. 4		rect (Instr. 4)			
Common Stock, \$0.01 Par Value (1)		04/14/2022				A		30,000	A	\$ 2.91 (2)	430,000		I	By TRad Fam Fou	off		
Common Stock, \$0.01 Par Value											3,898,100		D				
Reminder:	Report on a s	separate line	for each			•		Pe co the	rsons wi ntained i form di	no res n this splays	form a	to the collector to the	ired to res	pond u	nless	SEC 14	74 (9-02)
		1		Table II		outs, calls, v											
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transact Date (Month/Dat			Date, if	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	an (M	d Expiration Date Ionth/Day/Year)		e A U S	Title and mount of inderlying ecurities instr. 3 and		Securities Beneficially Owned Following Reported		O. Ownership orm of Derivative ecurity: Direct (D) r Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code V	(A) (D)	Ex	ate ercisable	Expira Date	ation T	Amount or Number of Shares					

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Radoff Bradley Louis C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022	X					

Signatures

	/s/ Radoff Bradley Louis	04/15/2022
٠	**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The shares of Common Stock are directly held by The Radoff Family Foundation (the "Radoff Foundation"). Mr. Radoff is a director of the Radoff Foundation and may be (1) deemed to beneficially own the shares of Common Stock held by the Radoff Foundation. Mr. Radoff disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- The price reported in column 4 is a weighted average price. These shares were purchased in multiple transaction prices ranging from \$2.91 to \$2.9155 inclusive. The (2) reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.